Christian Agboton
0000-0002-1178-2429
Takeda Pharmaceutical Company
31 papers found
Refreshing results…
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study
Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease
P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe
Su463 VEDOLIZUMAB RATES OF MUCOSAL HEALING IN CROHN'S DISEASE: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF REAL-WORLD DATA
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis
Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS a MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
Mo1811 REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NAÏVE NONCOMPLICATED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE EVOLVE STUDY
Sa1741 a REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
675 Measuring Serum Vedolizumab and Antibodies to Vedolizumab: Comparison of Four Commercially Available Clinical Laboratory Assays to the Assay Used in Vedolizumab Development
Su1866 – Integrating Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: Results from a Network Meta-Analysis
Sa1878 – Effects of Subcutaneous Vedolizumab on Health-Related Quality of Life and Work Productivity in Patients with Ulcerative Colitis: Results from the Phase 3 Visible 1 Trial
Tu1722 – Darvadstrocel Treatment Outcomes in Crohn's Disease Patients with Complex Perianal Fistulas: the Role of Tnfi Co-Treatment in Admire Cd
Attributes influencing parental decision-making to receive the Tdap vaccine to reduce the risk of pertussis transmission to their newborn – outcome of a cross-sectional conjoint experiment in Spain and Italy
P491 INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel
P436 Darvadstrocel treatment outcomes in Crohn’s disease patients with complex perianal fistulas: the role of TNFi co-treatment in ADMIRE CD
Missing publications? Search for publications with a matching author name.